| The consensus molecular subtypes of colorectal cancer J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ... Nature medicine 21 (11), 1350-1356, 2015 | 4943 | 2015 |
| Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118-122, 2014 | 924 | 2014 |
| A new measure for functional similarity of gene products based on Gene Ontology A Schlicker, FS Domingues, J Rahnenführer, T Lengauer BMC bioinformatics 7, 1-16, 2006 | 859 | 2006 |
| MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling S Huang, M Hölzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ... Cell 151 (5), 937-950, 2012 | 495 | 2012 |
| Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition P Roepman, A Schlicker, J Tabernero, I Majewski, S Tian, V Moreno, ... International journal of cancer 134 (3), 552-562, 2014 | 424 | 2014 |
| Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014 | 359 | 2014 |
| Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines A Schlicker, G Beran, CM Chresta, G McWalter, A Pritchard, S Weston, ... BMC medical genomics 5, 1-15, 2012 | 306 | 2012 |
| The implications of alternative splicing in the ENCODE protein complement ML Tress, PL Martelli, A Frankish, GA Reeves, JJ Wesselink, C Yeats, ... Proceedings of the National Academy of Sciences 104 (13), 5495-5500, 2007 | 251 | 2007 |
| ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy FH Groenendijk, J de Jong, EEF van de Putte, M Michaut, A Schlicker, ... European urology 69 (3), 384-388, 2016 | 225 | 2016 |
| Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer M Michaut, SF Chin, I Majewski, TM Severson, T Bismeijer, L De Koning, ... Scientific reports 6 (1), 1-13, 2016 | 205 | 2016 |
| First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors TA Yap, DSP Tan, A Terbuch, R Caldwell, C Guo, BC Goh, V Heong, ... Cancer discovery 11 (1), 80-91, 2021 | 199 | 2021 |
| The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer models AM Wengner, G Siemeister, U Lücking, J Lefranc, L Wortmann, P Lienau, ... Molecular cancer therapeutics 19 (1), 26-38, 2020 | 185 | 2020 |
| Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers AM Sieuwerts, S Willis, MB Burns, MP Look, MEMV Gelder, A Schlicker, ... Hormones and Cancer 5, 405-413, 2014 | 180 | 2014 |
| Improving disease gene prioritization using the semantic similarity of Gene Ontology terms A Schlicker, T Lengauer, M Albrecht Bioinformatics 26 (18), i561-i567, 2010 | 146 | 2010 |
| Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer L Henneman, MH van Miltenburg, EM Michalak, TM Braumuller, ... Proceedings of the National Academy of Sciences 112 (27), 8409-8414, 2015 | 141 | 2015 |
| FunSimMat: a comprehensive functional similarity database A Schlicker, M Albrecht Nucleic acids research 36 (suppl_1), D434-D439, 2007 | 110 | 2007 |
| A vulnerability of a subset of colon cancers with potential clinical utility L Vecchione, V Gambino, J Raaijmakers, A Schlicker, A Fumagalli, ... Cell 165 (2), 317-330, 2016 | 107 | 2016 |
| Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus C Welsch, FS Domingues, S Susser, I Antes, C Hartmann, G Mayr, ... Genome biology 9, 1-18, 2008 | 102 | 2008 |
| Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance M Quanz, E Bender, C Kopitz, S Grünewald, A Schlicker, W Schwede, ... Molecular cancer therapeutics 17 (11), 2285-2296, 2018 | 95 | 2018 |
| Computational analysis of human protein interaction networks F Ramirez, A Schlicker, Y Assenov, T Lengauer, M Albrecht Proteomics 7 (15), 2541-2552, 2007 | 91 | 2007 |
Lodewyk WesselsProfessor of Computational Cancer BiologyVerified email at nki.nl
